FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| 4DX | $4.00 |
|
$7.55 | $1.40 | -72.7 |
$4.50 |
|
| AT1 | $0.02 | 0.00% | $0.05 | $0.02 |
|
||
| AVE | $0.02 | 0.00% | $0.03 | $0.01 |
|
||
| AYA | $3.25 | 0.00% | $6.49 | $2.51 |
$6.00 |
|
|
| BB1 | $0.66 | 0.00% | $1.11 | $0.52 |
$1.76 |
|
|
| BRN | $0.13 | 0.00% | $0.26 | $0.11 |
|
||
| CAT | $3.14 |
|
$7.70 | $2.74 |
$5.16 |
|
|
| CBL | $0.06 | 0.00% | $0.10 | $0.03 |
|
||
| CGS | $3.31 |
|
$3.50 | $1.75 | 25.2 |
$3.885 |
|
| CMP | $0.26 | 0.00% | $0.45 | $0.22 |
|
||
| COH | $130.05 |
|
$296.50 | $88.74 | 25.1 |
$137.237 |
|
| CSX | $0.49 | 0.00% | $0.74 | $0.32 |
|
||
| CTE | $1.15 |
|
$1.40 | $0.86 |
|
||
| CU6 | $2.03 |
|
$5.87 | $1.80 |
$6.40 |
|
|
| CVB | $0.02 | 0.00% | $0.13 | $0.02 |
|
||
| EBR | $0.26 | 0.00% | $1.47 | $0.24 |
$1.275 |
|
|
| EIQ | $0.55 | 0.00% | $1.88 | $0.18 |
$0.983 |
|
|
| EMV | $1.60 |
|
$1.96 | $1.47 |
$3.15 |
|
|
| EYE | $0.14 | 0.00% | $0.21 | $0.10 |
|
||
| FPH | $37.31 |
|
$37.78 | $26.51 | 47.5 |
|
|
| IME | $0.30 |
|
$0.47 | $0.23 |
$0.37 |
|
|
| IMR | $1.48 |
|
$2.25 | $1.28 |
$2.90 |
|
|
| IPD | $0.01 | 0.00% | $0.05 | $0.00 |
$0.015 |
|
|
| LDX | $0.11 |
|
$0.33 | $0.08 |
$0.25 |
|
|
| MX1 | $0.05 | 0.00% | $0.12 | $0.01 |
$0.06 |
|
|
| NAN | $2.88 |
|
$4.76 | $2.64 | 73.8 |
$3.633 |
|
| ONE | $0.14 | 0.00% | $0.41 | $0.13 |
$0.42 |
|
|
| PCK | $0.10 | 0.00% | $0.35 | $0.04 |
|
||
| PEB | $0.19 |
|
$0.27 | $0.12 |
|
||
| PGC | $0.14 | 0.00% | $0.33 | $0.13 | 8.2 |
$0.23 |
|
| PME | $158.09 |
|
$305.55 | $107.75 | 81.3 |
$225.833 |
|
| RAP | $0.02 | 0.00% | $0.07 | $0.02 |
|
||
| RMD | $31.99 |
|
$43.29 | $25.50 | 18.2 |
$38.875 |
|
| SHG | $0.18 |
|
$0.35 | $0.17 |
|
||
| SLD | $0.45 |
|
$1.56 | $0.36 |
$1.885 |
|
|
| SOM | $0.29 |
|
$0.95 | $0.29 | 12.6 |
$0.76 |
|
| TRJ | $0.26 |
|
$0.87 | $0.15 | 8.3 |
$0.55 |
|
-1.72% 
12.5% Previous Stories
Dr Boreham’s Crucible: 4D Medical
Apr 23 2024
The New Criterion’s Tim Boreham uncovers the potential of 4D Medical in the USA
Uptrend Resumed For ResMed
Mar 19 2024
Shares in ResMed seem positioned for a new 2024 high, reports Michael Gable of Fairmont Equities
Dr Boreham’s Crucible: Cochlear
Feb 28 2024
The New Criterion’s Tim Boreham explains the business case for Cochlear
Rudi Interviewed: Ongoing Potential In Technology & Growth
Feb 19 2024
It has become the 'unofficial' tradition in recent years: an interview with Livewire Markets ahead of yet another corporate reporting…
Dr Boreham’s Crucible: Artrya
Feb 15 2024
Artificial intelligence and some valuable experiences should benefit heart device developer Artrya, Tim Boreham explains
ResMed Recovery Turns Into Hollywood Script
Jan 31 2024
More troubles for key competitor Philips/Respironics suggests there could be more momentum shifting in ResMed’s favour
ResMed Makes A Comeback
Jan 29 2024
ResMed’s December quarter showed long-awaited margin improvement and relieved market fears of the impact of weight-loss drugs
ResMed: The Recovery Has Begun
Jan 23 2024
Michael Gable of Fairmont Equities observes market dynamics for ResMed have changed for the better with price action suggesting higher prices are on the cards
Dr Boreham’s Crucible: Pro Medicus
Oct 23 2023
Tim Boreham highlights the significance of a new contract win for Pro Medicus and the company’s AI capacity
Dr Boreham’s Crucible: Cyclopharm
Oct 09 2023
FDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports
Latest News
| 1 |
AIC Mines’ Second Copper Hub Excites2:23 PM - Commodities |
| 2 |
Vitrafy Eyes US Blood Breakthrough11:00 AM - Small Caps |
| 3 |
Australian Listed Real Estate Tables – 06-10-202610:45 AM - Weekly Reports |
| 4 |
More Upside Ahead For Nasdaq10:30 AM - Technicals |
| 5 |
Uranium Week: U308 Price Bucks Rising Yields10:00 AM - Weekly Reports |